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Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated
with lower tissue triglyceride and higher plasma catecholamines
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Slower weight gain and less visceral fat had been observed when rats fed a high-fat diet were supplemented with freeze-dried bitter melon (BM) juice; the
metabolic consequences and possible mechanism(s) were further explored in the present study. In a 4-week experiment, rats were fed a low-fat (70 g/kg) or a
high-fat (300 g/kg) diet with or without BM (7.5 g/kg or 0.75%). BM-supplemented rats had lower energy efficiency, visceral fat mass, plasma glucose and
hepatic triacylglycerol, but higher serum free fatty acids and plasma catecholamines. In the second experiment, 7-week BM supplementation in high-fat diet
rats led to a lowering of hepatic triacylglycerol (P,0·05) and steatosis score (P,0·05) similar to those in rats fed a low-fat diet. BM supplementation did
not affect serum and hepatic cholesterol. However, plasma epinephrine and serum free fatty acid concentrations were increased (P,0·05). In the third exper-
iment, BM(7.5 and 15 g/kg) and 1·5 % BM lowered triacylglycerol concentration in red gastrocnemius and tibialis anterior (P,0·05) muscle, but a dose–
response effect was not observed. These data suggest that chronic BM feeding leads to a general decrease in tissue fat accumulation and that such an effect is
mediated in part by enhanced sympathetic activity and lipolysis. BM or its bioactive ingredient(s) could be used as a dietary adjunct in the control of body
weight and blood glucose.
Bitter melon: Adiposity: Triacylglycerol: Catecholamines
Diabetes represents a major public health concern, and its preva-
lence continues to escalate worldwide (Mokdad et al. 2003).
A large proportion of diabetics do use herbs and other dietary sup-
plements as adjuncts to traditional treatments (Yeh et al. 2003).
Bitter melon (Momordica charantia, BM), as the most popular
plant used by diabetics (Marles & Farnsworth, 1995), is widely
grown in tropical areas. The efficacy and safety of BM have
been the subject of several recent reviews (Raman & Lau,
1996; Shapiro & Gong, 2002; Basch et al. 2003; Yeh et al.
2003; Grover & Yadav, 2004). Despite the need for more infor-
mation in randomised controlled trails, BM-induced decreases
in blood glucose appear to be a recognised effect, and no serious
adverse effects on humans have been reported. Since the blood
glucose-lowering effect is demonstrable with a single oral dose,
the acute effect has been attributed to the presence of an insu-
lin-like polypeptide in BM (Khanna et al. 1981), a decrease in
glucose absorption (Meir & Yaniv, 1985) or an increase in hepatic
glucose utilisation (Shibib et al. 1993). The mechanisms of
actions of BM to lower blood glucose remain inconclusive.
Longer-term studies, however, reveal additional potential health
benefits of BM.
In our recent study (Chen et al. 2003), chronic BM supplemen-
tation not only improved glucose tolerance and lowered plasma
glucose, but also reduced visceral fat mass and energy efficiency
(EE) in rats fed a high-fat (HF) diet. As the latter observations are
not attributable to decreases in energy intake or apparent fat
absorption, some effects on lipid metabolism were suggested.
The effects of BM feeding on plasma lipids in rats have been
reported in normal and chemically induced diabetic rats, with
mixed results (Singh et al. 1989; Platel et al. 1993; Jayasooriya
et al. 2000; Ahmed et al. 2001; Virdi et al. 2003). Given that
the plasma free fatty acid (FFA) concentration was elevated in
rats fed the BM-supplemented HF diet (Chen et al. 2003), the
objectives of the present study were to determine whether a
reduced fat content in tissues is a general phenomenon and to
begin to search for further evidence of an enhanced lipolysis by
monitoring sympathetic activity. Accordingly, the triacylglycerol
(TG) contents of major organs involved in insulin resistance, and
plasma catecholamines, were determined in a series of three sep-
arate experiments.
Materials and methods
Freeze-dried bitter melon juice and experimental diets
Procedures described previously were followed (Chen et al.
2003). Unripe BM fresh fruits were purchased from a local
market. Seeds were removed and juice was extracted using an
electric juicer. After 72 h of freeze-drying, the yield was about
16 g powder per kilogram fresh fruit. The BM powder was kept
in airtight containers at 2708C until use.
The formulation of the powder diets was based on the AIN-93G
recommendation (American Institute of Nutrition, 1993). The low
fat (LF) diet contained 70 g fat/kg diet. The HF diet (300 g fat/kg
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diet) was obtained by adding Crisco shortening (Procter &
Gamble, Cincinatti, OH, USA), at the expense of cornstarch.
The freeze-dried BM juice powder was also added at the expense
of cornstarch (Table 1).
Animals
All animal protocols were approved by the Committee on the Use
of Live Animals in Teaching and Research at The University of
Hong Kong. The procedures were performed in accordance with
the NIH Guide for the Care and Use of Laboratory Animals
(National Institutes of Health, 1996). Rats were obtained, at
6 weeks of age, from the existing colony in the animal unit of
the Medicine Faculty. They were housed individually in rectangu-
lar, hanging wire cages in an environmentally controlled room
(12 h cycle with lights on at 07.00 h; 22^28C). The rats were
given free access to water and consumed laboratory food (Lab
Diet – The Richmond Standard; PMI Nutrition International
Inc., St Louis, MO, USA) until they were assigned to individual
groups. The rats were weighed twice a week. Food cup and
spillage were weighed daily, and reported intakes were corrected
for spillage. At the end of an experiment, rats that had been food-
deprived for 8 h were killed by decapitation. Blood was collected;
serum and plasma were stored at 2708C. Liver, visceral fat (Chen
et al. 2003), tibialis anterior and the red medial part of gastrocne-
mius (Franch et al. 2002) were excised, frozen and stored in
liquid N2 until analysis.
Three experiments were conducted. In experiment 1, BM and
HF were introduced to the rats at the beginning. In order to
assess the impact of BM supplementation on overweight rats,
male rats were pre-exposed to an HF diet for 4 weeks in experi-
ment 2. The experiment was also designed to compare the effect
of BM supplementation on the HF-diet rats with those switched
from an HF to an LF diet. In the last experiment, female rats
were used with the assumption that if BM affects body weight,
the effect might be better demonstrated in slow-growing adult
females.
Experiment 1. Male Sprague–Dawley rats (170–190g, n 32)
were randomly assigned to one of four dietary groups. They were
fed one of the following diets for 4 weeks (Table 1): LF;
LF þ BM (0·75 %, w/w); HF; or HF þ BM (0·75 %, w/w).
Experiment 2. Male Sprague–Dawley rats (170–190g) were
fed an LF (n 7) or HF (n 32) diet. Beginning at week 5, the HF
rats were randomly assigned to one of the four diets for 7
weeks (Table 1): HF, HF þ 0·75 % BM (HF/HF þ BM), LF
(HF/LF) and LF þ 0·75 % BM (HF/LF þ BM).
Experiment 3. Female Sprague–Dawley rats (140–160g)
were fed an LF (n 5) or HF (n 25) diet for 6 weeks. At the begin-
ning of week 7, some HF rats continued to receive the HF diet
(HF, n 8) while the others were switched to an HF þ 0·75 %
BM (n 9) or HF þ 1·5 % BM (n 8) diet for 9 weeks.
Measurements
Plasma glucose was assayed immediately using a commercially
available glucose oxidase kit (Kit No. 510-A; Sigma Chemical
Co., St Louis, MO, USA). Serum FFA level was determined by
an enzymatic colorimetric assay (NEFA C test kit; Wako,
Osaka, Japan). Serum insulin was determined by ELISA (Merco-
dia rat insulin 10-1124-01; Mercordia AB, Uppsala, Sweden).
Serum TG was measured enzymatically (GPO-HDAOS
method, L-Type TG-H kit; Wako). With this method, free gly-
cerol was removed in a reaction prior to the hydrolysis of TG
and colour development. Serum total cholesterol was determined
by a cholesterol oxidase-HDAOS method (L-Type CHO-H kit;
Wako). Lipids in liver and muscles were first extracted with a
mixture of chloroform and methanol (Folch et al. 1957). Lipids
were dissolved in tert-butyl alcohol, and Triton X-100–methanol
(1:1,) was added before enzymatic assays for TG and cholesterol,
were carried out (Danno et al. 1992).
For plasma catecholamines, a portion of the blood was col-
lected in chilled lithium heparin tubes containing 50ml of a mix-
ture of EDTA and glutathione (4·75 g EDTA and 3·00 g
glutathione dissolved in 50 ml double-distilled deionised water
and the pH adjusted to 6·8; Forster & Macdonold, 1999).
Plasma epinephrine and norepinephrine were measured by
reverse-phase liquid chromatography with electrochemical detec-
tion. Plasma epinephrine and norepinephrine were extracted with
Table 1. Composition of experimental diets*
Low-fat diet (LF) High-fat diet (HF)
LF LF þ 0·75 % BM HF HF þ 0·75 % BM HF þ 1·5 % BM
Casein (g/kg)† 200·0 200·0 255·0 255·0 255·0
Cornstarch (g/kg)† 529·5 522·0 231·5 224·0 216·5
Sucrose (g/kg)† 100·0 100·0 100·0 100·0 100·0
Cellulose (fibre) (g/kg)† 50·0 50·0 50·0 50·0 50·0
Corn oil (g/kg)‡ 70·0 70·0 70·0 70·0 70·0
Shortening (g/kg)‡ 0 0 230·0 230·0 230·0
Mineral mix (g/kg)† 35·0 35·0 45·0 45·0 45·0
Vitamin mix (g/kg)† 10·0 10·0 13·0 13·0 13·0
Miscellaneous (g/kg)§ 5·514 5·514 5·514 5·514 5·514
Bitter melon (BM) (g/kg)k 0 7·5 0 7·5 15·0
Energy density (MJ/kg){ 16·44 16·32 21·01 20·88 20·76
* Based on the AIN-93G diet (American Institute of Nutrition, 1993).
† Harlan Teklad (Madison, WI, USA).
‡ Mazola corn oil (CPC Int., Malaysia); Crisco shortening: Partially hydrogenated vegetable shortening from Procter & Gamble Co.
(Cincinatti, OH, USA).
§ Choline bitartrate (2·5 g/kg), L-cystine (3·0 g/kg) and tert-butylhydroquinone (0·014 g/kg).
kAdded as freeze-dried bitter melon juice (BM).
{Based on Atwater factors: 16·74 MJ/kg for protein and carbohydrates, 37·66 MJ/kg for fat.
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acid-washed alumina (type WA-4; Sigma Chemicals) and des-
orbed with acetic acid buffer. 3,4-Dihydroxybenzylamine hydro-
bromide was used as an internal standard. Samples were
injected into an HPLC system. The mobile phase (200 ml metha-
nol, 9·02 g sodium acetate, 0·372 g disodium EDTA and 100 mg
sodium dodecyl sulphate dissolved in 1000 ml deionised water,
pH 5·1) was pumped (PM-80, Bioanalytical Systems, West Lafay-
ette, IN, USA) through a 3mm octadecylsilane column (PHASE-
II, Part No. MF 6213, 100 £ 3·2 mm; Bioanalytical Systems) at a
rate of 0·7 ml/min. A dual glass carbon electrode was connected to
an amperometric detector (LC-4C; Bioanalytical Systems). The
potential was set at þ0·85 V with an Ag/AgCl reference elec-
trode. The detector range was set at 0·1mA. Peaks were quantified
by area (Allchrom software; Alltech Association Inc., Deerfield,
IL, USA). The within-assay CV was 3·8 % and 5·6 % for epineph-
rine and norepinephrine, respectively. The between-assay CV was
9·9 % for epinephrine and 8·1 % for norepinephrine. Recovery
was 92·4 % for epinephrine and 91·7 % for norepinephrine.
Liver histology
The right lobe of the liver from each rat was fixed overnight in
10 % buffered formalin solution and embedded in paraffin. Histo-
logical sections (4mm) were prepared and stained with haema-
toxylin-eosin. Three sections (12mm apart) from each rat were
graded blindly. A score of 0 to 3 was used to describe the
extent of steatosis (Hourigan et al. 1999; Friedenberg et al.
2003). A zero score represents normal liver structure in which
lipid accumulation in the hepatocytes is not observed. A score
of 1 depicts mild lipid infiltration (occurring in ,30 % hepato-
cytes), a score of 2 depicts moderate lipid infiltration (occurring
in 30–70 % hepatocytes), whereas a score of 3 indicates severe
lipid infiltration (occurring in .70 % of hepatocytes). In addition,
the presence or absence of liver cell injury, including inflam-
mation, fibrosis and necrosis, was also noted.
Statistical methods
Data are expressed as means with their standard errors. Analyses
were carried out with the Statistical Package for the Social
Science (SPSS for Windows, version 10.1; Chicago, IL, USA).
In experiment 1, two-way ANOVA was used to examine the
effects of dietary fat (two levels: LF and HF), BM (two
levels: with and without BM) and their interactions. In exper-
iments 2 and 3, data were analysed by one-way ANOVA fol-
lowed by post hoc Duncan’s multiple range tests to determine
treatment effect and compare differences among group means.
Univariate analysis was also carried out to control for differences
in energy intake. A non-parametric Kruskal–Wallis test was
employed to determine the effect of dietary manipulations on
steatosis score. When the scores between two groups were com-
pared, the Mann–Whitney test was applied. Correlation analysis
was performed to determine the relationship between two vari-
ables. Statistical significance was accepted at P,0·05.
Results
Weight gain and energy intake
In experiment 1, significant effects of dietary fat and BM on
weight gain and EE were observed (Table 2). Rats fed an HF-
diet consumed more energy. However, BM supplementation did
not affect the energy intake of rats. The weight gain of rats
given BM was 6·9 % and 9·4 % less than that of their respective
LF and HF controls. As a result, BM supplementation led to a
reduction in EE (P,0·05).
The growth and EE data for rats in experiment 2 have been
reported (Chen et al. 2003; marked with ‡ in Table 4). Rats in
the HF/HF þ BM group gained less weight and had a lower EE
than the HF group (P,0·05). The HF/LF or HF/LF þ BM rats
all gained less weight and had a lower EE (over 7 weeks,
P,0·05) than rats fed an LF-diet for the entire study period.
In experiment 3, EE progressively decreased with increase in
BM (4·6, 3·3 and 2·8 for HF, HF þ 0·75 % BM and HF þ 1·5 %
BM, respectively). Weight gain for the three groups over a
period of 9 weeks was 124, 78 and 67 g respectively.
Glucose, insulin, free fatty acids and visceral fat mass
In experiment 1, the final concentration of plasma glucose was
higher in rats fed an HF diet than in rats fed an LF diet
(Table 3; P,0·05). BM supplementation normalised plasma glu-
cose (P,0·05). However, serum insulin concentration and insulin
resistance index were similar among the four groups.
There were dietary fat and BM effects on serum FFA and visc-
eral fat mass (Table 3; P,0·05). As dietary fat content increased,
serum FFA concentration decreased. In contrast, BM supplemen-
tation increased serum FFA concentration. As expected, HF feed-
ing elevated visceral fat mass, whereas BM supplementation
lowered visceral fat accumulation. Among the rats in experiment
1, visceral fat mass correlated negatively with serum FFA
(r 20·61, n 32, P 0·001) but positively with plasma glucose
(r¼0·48, n 32, P¼0·006).
Table 2. Growth and feed intake of male rats after 4 weeks of bitter melon (BM) supplementation (experiment 1) (Male rats given a low-fat diet (LF) LF þ 0·75 %
BM, high-fat diet (HF) or HF þ 0·75 % BM for 4 weeks)
LF LF þ 0·75 % BM HF HF þ 0·75 % BM P value (two-way ANOVA)
Mean SE Mean SE Mean SE Mean SE Fat BM Fat £ BM
n 8 8 8 8
Initial body weight (g) 186 2 187 3 184 3 186 3
Body weight at week 4 (g) 446 6 430 13 492 10 465 6 0·001 0·031 0·584
Weight gain (g/4 weeks) 260 6 242 12 308 8 279 5 0·01 0·011 0·520
Energy intake (MJ/4 weeks) 14·8 0·4 14·5 0·4 15·9 0·6 15·7 0·3 0·015 0·595 0·973
EE (g gain/MJ) 17·6 0·3 16·7 0·5 19·4 0·3 17·8 0·3 0·001 0·001 0·403
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Plasma catecholamines
In experiment 1, plasma epinephrine and norepinephrine concen-
trations were increased with BM supplementation (Table 3;
P,0·05).
In experiment 2, plasma epinephrine concentration was lower
in the HF rats compared with the LF rats (Table 4; P,0·05).
However, the plasma epinephrine concentration of the HF/
HF þ BM rats was 44·8 % higher than that in the HF rats
(P,0·05) and was comparable to that of the LF rats. In this
experiment, plasma norepinephrine concentration did not differ
among groups. Nevertheless, serum FFA was found to correlate
positively with both epinephrine (r 0·34, n 39, P¼0·034) and nor-
epinephrine (r 0·33, n 39, P¼0·038).
Plasma catecholamines were not measured in experiment 3.
Muscle triacylglycerol and cholesterol
In experiment 3, the TG concentration in both red gastrocnemius
and tibialis anterior was higher in HF rats than in LF rats (Fig. 1;
P,0·05). The addition of BM to the HF-diet lowered TG concen-
trations in both types of skeletal muscle (P,0·05).
In all experiments, muscle cholesterol concentration was not
affected by dietary manipulations (data not shown).
Hepatic triacylglycerol, cholesterol and histopathology
In experiment 1, feeding an HF-diet led to rats with a greater liver
weight, but BM had no impact on liver weight (Table 3). Interest-
ingly, there were effects of dietary fat and BM on hepatic TG con-
tent (similar results if based on per gram of liver). The
accumulation of TG caused by HF feeding was reduced by
18 % upon BM supplementation (P,0·05).
In experiment 2, the HF/LF rats and HF/HF þ BM rats had a
similar hepatic TG content that was 40·5 % and 36·9 % lower
than that of the HF rats (Table 4; P,0·05).
In experiment 3, liver weight was no different among the four
groups (data not shown). The hepatic TG content of the LF,
HF þ 0·75 % BM and HF þ 1·5 % BM groups was similar but
significantly lower than that of the HF group (Fig. 1).
Steatosis scores on liver sections from the rats of experiments 2
and 3 are shown in Fig. 2. In experiment 2, the HF/LF, HF/
LF þ BM and HF/HF þ BM rats all had steatosis scores that
were not different from the LF rats but were lower than the HF
rats (P,0·05). In experiment 3, steatosis scores decreased pro-
gressively with BM supplementation. Scores from the
HF þ 1·5 % BM rats were similar to those of the LF rats but
were lower than those of the HF rats (P,0·05).
Photomicrographs of liver sections (experiment 2) characteris-
ing the different stages of steatosis are shown in Fig. 3. Fig. 3A
represents samples with a score of zero. Over half of the rats
fed the LF diet received this score. Rats switched to an LF diet
(HF/LF) or fed diets supplemented with varying doses of BM
had mild (score of 1; Fig. 3B) to moderate (score of 2; Fig. 3C)
macro- and microvesicular steatosis. Macro- and microvesicular
steatosis, if present, was predominantly located in the periportal
area. As expected, fatty liver was observed in most rats fed an
HF diet. These rats had moderate to severe (score of 3;
Fig. 3D), mixed micro- and macrovesicular steatosis and even
foamy degeneration (Fig. 3E) in the liver. There was no dilatationT
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and congestion in the central veins and in the surrounding sinu-
soids, and no fibrosis and necrosis in any section.
In all experiments, BM supplementation had no effect on serum
TG or serum or hepatic cholesterol concentration.
Discussion
Supplementation with BM slows weight gain and improves insu-
lin sensitivity in rats fed an HF diet. The present results extend
our previous study to indicate that the chronic consumption of
BM leads to a general decrease in the TG content of the major
organs. Elevated plasma catecholamines and serum FFA suggest
an enhanced sympathetic activity and lipolytic process. These
data are consistent with the view that bioactive ingredients in
BM possess anti-obesity properties that might be beneficial to
body weight and glycaemic control.
In BM rats, a lower adipose tissue mass did not lead to lipid
deposition in other major organs. In fact, BM-supplemented rats
had less TG in their livers (Tables 3 and 4, Fig. 1) and skeletal
muscle (Fig. 1). This generalised reduction in lipid deposition
in the major organs suggests interferences of intermediary metab-
olism by ingredients present in BM. Rats fed an HF diet have
dampened fatty acid synthesis (Romsos & Leveille, 1974), and
dietary fatty acids in chylomicrons are taken up by peripheral tis-
sues first before arriving at the liver. Thus, the lower visceral fat
and hepatic TG content observed in BM-supplemented rats could
be attributable to a decrease in peripheral clearance and enhanced
utilisation, respectively. As insulin promotes fat deposition by sti-
mulating lipoprotein lipase (Robinson & Speake, 1989), positive
correlations between the insulin resistance index and visceral fat
mass in experiment 2 (r 0·653, n 39, P¼0·001) and experiment
3 (r 0·847, n 30, P¼0·001) do not support an effect involving
decreased peripheral uptake. However, a suppressive effect on
de novo fatty acid synthesis could not be ruled out because
LF þ BM rats had 10 % less visceral fat and 48·5 % less hepatic
TG than LF rats (Table 3).
The elevated concentration of plasma catecholamines is an
original observation. Plasma norepinephrine is released from
sympathetic nerve endings, and plasma epinephrine is secreted by
chromaffin cells of the adrenal medulla. A catecholamine-mediated
lipolytic process in BM rats is supported by the positive correlations
between serum FFA and plasma catecholamines (see Results). As
the decline in weight gain is associated with an enhanced sympath-
etic activity, the impact of BM on metabolism is reminiscent of that
of green tea. Catechin in green tea has been implicated in playing a
role in promoting thermogenesis via sympathetic activation
(Dulloo et al. 2000). Although BM is not known to contain cate-
chin, it is rich in a-eleostearic acid (Yuwai et al. 1991; Suzuki
et al. 2001), a conjugated linolenic acid that could give rise to con-
jugated linoleic acid (Tsuzuki et al. 2003). The latter has been
shown to enhance sympathetic activity (Ohnuki et al. 2001).
Although unlikely, the possibility that sympathetic activation is
the consequence of a stress response cannot be ruled out. Activation
of the hypothalamo-pituitary–adrenal axis will lead to the secretion
of glucocorticoid. This hormone is known to antagonise the effects
of insulin and promote lipolysis. Because the overall effects of BM
supplementation are improved glucose tolerance (Chen et al. 2003)
and insulin sensitivity (Table 3), an active role for glucocorticoid in
mediating the effects of BM is doubtful.
Blood FFA concentration is determined by lipolytic activity as
well as by the rate of uptake by tissues for oxidation or re-ester-
ification. Liver is a key site of metabolic integration. The results
of experiments 2 and 3 clearly demonstrated the ability of BM
supplementation to reverse steatosis and normalise hepatic TG
content. In 7 weeks, the hepatic TG level was reduced by 37 %
and 40·5 % when rats switched from an HF to an HF þ BM or
LF diet (experiment 2). In other words, the addition of BM to
an HF diet produced effects similar to those of an LF diet. The
lowering of hepatic TG is not limited to rats fed HF diets. Rats
given a LF diet with (Table 4) or without (Table 3) prior exposure
to an HF diet also had a lower hepatic TG upon BM supplemen-
tation. This effect is in general agreement with that reported by
others who gave BM pulp (Jayasooriya et al. 2000) or juice
(Ahmed et al. 2001) to rats fed an LF diet. The anti-fatty liver
effect of BM may be of clinical interest as diseases such as dia-
betes, alcoholism and hepatitis can cause steatosis.
The lower TG content of the skeletal muscle of BM-
supplemented rats is another important and original observation
Table 4. Effects of bitter melon (BM) supplementation or low-fat diet (LF) on hormone and substrate concentrations of male rats previously exposed to a high-fat
diet (HF) (experiment 2)*†
LF HF/LF HF/LF þ BM HF HF/HF þ BM
Mean SE Mean SE Mean SE Mean SE Mean SE
n 7 8 8 8 8
Body weight at wk 11(g)‡ 610a 22 626a 13 620a 12 723c 16 675b 17
Weight gain (g/7 weeks)‡ 175b 11 146a 10 139a 8 235c 6 195b 7
Energy efficiency (g gain/MJ)‡ 7·0b 0·3 5·9a 0·4 5·9a 0·6 8·3c 0·2 7·1b 0·2
Visceral fat weight (g)‡ 45·4a 4·6 49·9a 3·9 46·9a 3·3 79·3c 4·5 66·9b 4·3
Serum free fatty acid (mmol/l)‡ 0·73ab 0·03 0·93c 0·08 0·92c 0·05 0·63a 0·06 0·82bc 0·07
Serum triacylglycerol (mmol/l) 2·2ab 0·3 3·1b 0·4 2·1a 0·4 2·1a 0·3 1·6a 0·3
Serum cholesterol (mmol/l) 3·7 0·3 3·8 0·3 4·0 0·3 3·7 0·4 3·4 0·3
Liver weight (g)‡ 20·3a 0·8 22·1ab 0·9 21·3a 0·8 24·1b 1·0 20·9a 0·8
Liver triacylglycerol (mmol/liver) 913·8a 129·1 756·1a 129·2 573·7 a 62·9 1270·0b 139·1 801·1a 137·1
Liver cholesterol (mmol/liver) 169·6 21·3 173·4 23·9 142·3 17·2 213·7 22·7 154·2 20·8
Plasma epinephrine (nmol/l) 64·1b 4·9 57·8ab 6·0 57·1ab 4·9 45·5a 4·6 65·9 b 4·6
Plasma norepinephrine (nmol/l) 29·9 2·9 31·6 7·7 33·2 3·9 32·1 3·9 42·0 5·3
* Male rats were given either an LF diet (n 7) or an HF diet (n 32) for 4 weeks. At the beginning of week 5, the HF rats were randomly assigned to one of the following groups and fed the
respective diets for an additional 7 weeks: LF fat (HF/LF), LF þ 0·75 % BM (HF/LF þ BM), HF (HF), and HF þ 0·75 % BM (HF/HF þ BM).
† Covariance: total energy intake. Means in a row not sharing a superscript letter are significantly different, P,0·05.
‡ Data from Chen et al. (2003).
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not previously reported. Skeletal muscle is an important meta-
bolic organ that is responsible for 40–50 % of total FFA disposal
(Jensen, 2003). Thus, it is generally considered to be the most
important site of insulin resistance (Kelley et al. 2002; Hegarty
et al. 2003). The present results showed that BM supplementation
decreased TG content in the oxidative-type (Peters et al. 2001)
red gastrocnemius and tibialis anterior muscles (experiment 3;
Fig. 1). At a dose of 0·75 % BM, TG content was lower than in
the unsupplemented HF group and similar to that of the LF
group. A dose–response effect was observed for tibialis anterior
but not for red gastrocnemius. The reduction of TG within
muscles may result from a decreased uptake of fatty acids or
from an increased capacity for lipid oxidation. The present data
suggest that increased lipid oxidation may be responsible, at
least in part, for the reduction of muscle TG in BM rats. The sig-
nificance of the latter phenomenon is further illustrated by a posi-
tive correlation between red gastrocnemius TG concentration and
insulin resistance index (r 0·652, n 30, P¼0·001).
A lack of effect of BM on serum and tissue cholesterol is con-
sistent with that reported by Virdi et al. (2003) and Jayasooriya
et al. (2000) but at variance with that of Platel et al. (1993)
and Singh et al. (1989). The reasons for these discrepant results
are not apparent and might be related to factors such as the
strain of rat, the presence of diabetes, the BM extract preparation
method and the duration of treatment.
The mechanisms whereby BM triggers a series of physiological
responses resulting in reduced body fat content and improved
insulin sensitivity remain to be elucidated. One consistent finding
in our experiments was that of an elevated serum FFA in BM-sup-
plemented rats. Because these rats actually had less tissue TG and
better glucose tolerance (Chen et al. 2003), the data do not sup-
port the general view that FFA induces insulin resistance
(Boden et al. 2002). It is speculated that, as ligands of peroxisome
proliferator-activated receptors, FFA might promote b-oxidation
Fig. 1. Triacylglycerol content in the muscle and liver of female rats fed a
high-fat diet supplemented with bitter melon (BM) (experiment 3). Rats were
given either a low-fat (LF; n 5) or a high-fat (HF; n 25) diet for 6 weeks. For
the following 9 weeks, some of the HF rats were given BM (0·75 % or 1·5 %)
supplementation. Values are means with their standard errors represented
by vertical bars. (n 5–9 rats). Univariate analysis with energy intake as cov-
ariate was performed. Mean values not sharing the same letters are signifi-
cantly different (P,0·05; post hoc Duncan’s multiple range test).
Fig. 2. Histopathological evaluation in the liver of rats. Each section was
ranked blindly as described in Materials and methods. In experiment 2 (A),
male rats were given either a low-fat (LF) or a high-fat (HF) diet for 4 weeks.
At the beginning of week 5, the HF rats were randomly assigned to one of
the following groups and fed the respective diets for an additional 7 weeks:
low fat (HF/LF), LF þ 7.5g/kg BM (HF/LF þ BM), HF (HF) and HF þ 7.5g/kg
BM (HF/HF þ BM). In experiment 3 (B), female rats were used (refer to Fig. 1
for experimental conditions). Values are means with their standard errors
represented by vertical bars. (n 5–9 rats). The overall significance of the
steatosis score was determined by the non-parametric Kruskal–Wallis test.
*P,0·05 v. HF group (Mann–Whitney test).
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and dissipate energy as heat via an up-regulation of the expression
of uncoupling proteins (Armstrong & Towle, 2001). To this end,
it is relevant to point out that an ethyl acetate extract of BM (seed
or flesh) has recently been shown to activate peroxisome prolif-
erator-activated receptor a and up-regulate the expression of the
acyl-CoA oxidase gene in H4IIEC3 hepatoma cells (Chao &
Huang, 2003).
In summary, BM supplementation elevates plasma catechol-
amines and serum FFA level but decreases hepatic and muscular
TG content. The data suggest that chronic BM feeding leads to a
general decrease in the TG content of the major organs. The latter
phenomenon may be mediated in part by enhanced sympathetic
activity, lipolysis and possibly lipid oxidation. The positive
effects of BM on glycaemia and steatosis warrant further studies
to isolate the bioactive ingredients and delineate the mechanisms
of actions. In addition to its being a popular vegetable in many
countries, the potential benefits of BM might be extended to
blood glucose and weight control.
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